- Home
- ACON vs INM Comparison
ACON vs INM Comparison
Compare ACON & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- INM
- Stock Information
- Founded
- ACON 2008
- INM 1981
- Country
- ACON United States
- INM Canada
- Employees
- ACON N/A
- INM N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- INM Health Care
- Exchange
- ACON Nasdaq
- INM Nasdaq
- Market Cap
- ACON 4.3M
- INM 4.4M
- IPO Year
- ACON 2022
- INM N/A
- Fundamental
- Price
- ACON $7.15
- INM $2.11
- Analyst Decision
- ACON Buy
- INM
- Analyst Count
- ACON 2
- INM 0
- Target Price
- ACON $481.00
- INM N/A
- AVG Volume (30 Days)
- ACON 9.0K
- INM 42.3K
- Earning Date
- ACON 08-14-2025
- INM 09-29-2025
- Dividend Yield
- ACON N/A
- INM N/A
- EPS Growth
- ACON N/A
- INM N/A
- EPS
- ACON N/A
- INM N/A
- Revenue
- ACON $62,948.00
- INM $4,920,990.00
- Revenue This Year
- ACON $145.39
- INM N/A
- Revenue Next Year
- ACON $145.45
- INM N/A
- P/E Ratio
- ACON N/A
- INM N/A
- Revenue Growth
- ACON 16.68
- INM N/A
- 52 Week Low
- ACON $6.20
- INM $1.72
- 52 Week High
- ACON $3,499.51
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- ACON 46.50
- INM 35.28
- Support Level
- ACON $6.82
- INM $2.22
- Resistance Level
- ACON $7.36
- INM $2.25
- Average True Range (ATR)
- ACON 0.35
- INM 0.08
- MACD
- ACON 0.01
- INM 0.00
- Stochastic Oscillator
- ACON 35.29
- INM 26.67
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.